Novantrone
(Mitoxantrone)ApprovedSmall molecule
EMD SeronoMitoxantrone is used to treat certain types of cancer (including leukemia and lymphoma) and to reduce disability progression in multiple sclerosis by slowing down the disease.[2] Novantrone is currently approved and in use across 33 indications[4].[1]
Novantrone is one of 647 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Approved.
33
Indications
99
Total Trials
13
Active Trials
646
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 33 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Novantrone
EMD SeronoApproved
Oncaspar
SServier
Preclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Tafasitamab
IncytePreclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
VP-16
FFundamenta Therapeutics, Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia19 trials
Show 16 more trials
Prostate Cancer13 trials
Show 10 more trials
Acute Lymphoblastic Leukemia8 trials
Show 5 more trials
Chemotherapy5 trials
Lymphoma4 trials
36 more indications
Acute Promyelocytic Leukemia3 trials
Follicular Lymphoma3 trials
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
Terminated·—·Phase 2·NCT00510887·14 enrolled
Neuromyelitis Optica2 trials
Newly Diagnosed2 trials
Diffuse Large B-Cell Lymphoma2 trials
Multiple Sclerosis2 trials
Leukemia2 trials
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·N/A·NCT01184898·36 enrolled
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia
Terminated·—·Phase 1·NCT02631252·1 enrolled
Acute Leukemia2 trials
Chronic Lymphocytic Leukemia2 trials
Mantle Cell Lymphoma2 trials
Myelodysplastic Syndrome2 trials
Acute Monocytic Leukemia1 trial
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT05313958·43 enrolled
T-cell acute lymphoblastic leukemia1 trial
Hematologic Malignancies1 trial
Myeloid Malignancies1 trial
Metastatic Prostate Cancer1 trial
Relapsing-Remitting Multiple Sclerosis1 trial
Precursor B-Cell Acute Lymphoblastic Leukemia1 trial
Relapsed/Refractory AML1 trial
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Terminated·—·Phase 1·NCT03735446·2 enrolled
Trial1 trial
Transplantation1 trial
Relapsed or Refractory1 trial
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Terminated·—·Phase 2·NCT02535806·2 enrolled
B-cell acute lymphoblastic leukemia1 trial
FLT3-mutated Acute Myeloid Leukemia1 trial
Acute Myeloid Leukaemia1 trial
Regulatory
FDA Approval Timeline[5]
Dec 23, 1987
NOVANTRONE
NDA NDA019297
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Novantrone drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Mitoxantrone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- DNA Topoisomerase II Alpha Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company